Endogenous viable cells in lyopreserved amnion retain differentiation potential and anti-fibrotic activity in vitro
Source abstract
Abstract
Human amniotic membrane (AM) has intrinsic anti-inflammatory, anti-fibrotic and antimicrobial properties. Tissue preservation methods have helped to overcome the short shelf life of fresh AM allowing "on demand" use of AM grafts. Cryopreserved AM that retains all native tissue components, including viable cells, has clinical benefits in treating chronic wounds. However, cryopreservation requires ultra-low temperature storage, limiting the use of cryopreserved products. To overcome this limitation, a new lyopreservation method has been developed for ambient storage of living tissues. The goal of this study was to investigate the viability and functionality of AM cells following lyopreservation. Fresh AM and devitalized lyopreserved AM (DLAM) served as positive and negative controls, respectively. Using live/dead staining, we confirmed the presence of living cells in viable lyopreserved AM (VLAM) and showed that these cells persisted up to 21 days in culture medium. The functionality of cells in VLAM was assessed by their differentiation potential and anti-fibrotic activity in vitro. With osteogenic induction, cells in VLAM deposited calcium within the membrane, a marker of osteogenic cells, in a time-dependent manner. The migration of human lung fibrotic fibroblasts in a scratch wound assay was reduced significantly in the presence of VLAM-derived conditioned medium. Quantitative PCR analyses indicated that VLAM reduced the expression of pro-fibrotic factors such as type I collagen and increased the expression of anti-fibrotic factors such as hepatocyte growth factor and anti-fibrotic microRNA in fibrotic fibroblasts. Taken together, these results demonstrate that endogenous cells in VLAM remain viable and functional post-lyophilization. STATEMENT OF SIGNIFICANCE: This study, for the first time, provides direct evidence showing that tissue viability and functional cells can be preserved by lyophilization. Similar to fresh amniotic membrane (AM), viable lyopreserved AM (VLAM) retains viable cells for extended periods of time. More importantly, these cells are functional and maintain their osteogenic differentiation potential and anti-fibrotic activity. Our results confirmed that the novel lyophilization method preserves tissue viability.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Mesenchymal stem cell research · Corneal Surgery and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. The role of allogenic amniotic membrane in burn treatment10.1097/BCR.0b013e31818b9e40 ↗
2. The grafting of preserved amniotic membrane to burned and ulcerated skin surfaces, substituting skin grafts
3. Understanding the impact of preservation methods on the integrity and functionality of placental allografts10.1097/SAP.0000000000001101 ↗
4. Properties of viable lyopreserved amnion are equivalent to viable cryopreserved amnion with the convenience of ambient storage10.1371/journal.pone.0204060 ↗
5. Soluble factors released by endogenous viable cells enhance the antioxidant and chemoattractive activities of cryopreserved amniotic membrane10.1089/wound.2015.0637 ↗
6. Retention of endogenous viable cells enhances the anti-inflammatory activity of cryopreserved amnion10.1089/wound.2015.0636 ↗
7. Angiogenic potential of cryopreserved amniotic membrane is enhanced through retention of all tissue components in their native state10.1089/wound.2015.0638 ↗
8. A comparative outcomes analysis evaluating clinical effectiveness in two different human placental membrane products for wound management10.1111/wrr.12503 ↗
9. Placental membranes for management of refractory cutaneous sinus tracts of surgical origin: a pilot study
10. Antimicrobial peptides secreted from human cryopreserved viable amniotic membrane contribute to its antibacterial activity10.1038/s41598-017-13310-6 ↗
11. Open-label extension phase of a chronic diabetic foot ulcer multicenter, controlled, randomized clinical trial using cryopreserved placental membrane
12. The efficacy and safety of Grafix((R)) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial10.1111/iwj.12329 ↗
13. Effectiveness of viable cryopreserved placental membranes for management of diabetic foot ulcers in a real world setting10.1111/wrr.12635 ↗
14. Anhydrobiosis10.1146/annurev.ph.54.030192.003051 ↗
15. Recent advances and future direction in lyophilisation and desiccation of mesenchymal stem cells10.1155/2016/3604203 ↗
16. A novel approach for the cryodesiccated preservation of tissue-engineered skin substitutes with trehalose10.1016/j.msec.2015.10.057 ↗
17. Morgan · 2009
18. Evaluation of the lyophilized platelets function by thromboelastography in an in vitro platelet transfusion model
19. Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion10.1073/pnas.92.2.397 ↗
20. Freeze-drying of mononuclear cells derived from umbilical cord blood followed by colony formation10.1371/journal.pone.0005240 ↗
21. Nuclear transfer of freeze-dried somatic cells into enucleated sheep oocytes10.1111/j.1439-0531.2008.01193.x ↗
22. Development of normal mice from oocytes injected with freeze-dried spermatozoa10.1038/nbt0798-639 ↗
23. Absence of antigenicity in freeze-dried skin allografts10.1016/S0011-2240(70)80099-2 ↗
24. The preservation of bone grafts by freeze-drying
25. Lyophilized veins as arterial interposition allografts10.1016/0011-2240(81)90102-4 ↗
26. Lyophilized auricular cartilage as a replacement for the interarticular disc of the craniomandibular joint. An experimental study in guinea pigs10.1016/S1010-5182(88)80066-0 ↗
27. A comparison of lyophilized amniotic membrane with cryopreserved amniotic membrane for the reconstruction of rabbit corneal epithelium10.1007/BF02932023 ↗
28. The use of trehalose-treated freeze-dried amniotic membrane for ocular surface reconstruction10.1016/j.biomaterials.2008.05.023 ↗
29. Sterilized, freeze-dried amniotic membrane: a useful substrate for ocular surface reconstruction10.1167/iovs.03-0752 ↗
30. A viable lyopreserved amniotic membrane modulates diabetic wound microenvironment and accelerates wound closure10.1089/wound.2018.0931 ↗
31. Intact human amniotic membrane differentiated towards the chondrogenic lineage10.1007/s10561-014-9454-9 ↗
32. Osteogenic differentiation of intact human amniotic membrane10.1016/j.biomaterials.2010.07.090 ↗
33. Anti-fibrotic effects of fresh and cryopreserved human amniotic membrane in a rat liver fibrosis model10.1007/s10561-012-9337-x ↗
34. Antifibrotic effects of human amniotic membrane transplantation in established biliary fibrosis induced in rats10.3727/096368916X692645 ↗
35. Anti-inflammatory and anti-fibrotic effects of human amniotic membrane mesenchymal stem cells and their potential in corneal repair10.1002/sctm.18-0042 ↗
36. Monitoring local cell viability in engineered tissues: a fast, quantitative, and nondestructive approach10.1089/107632703764664738 ↗
37. Accuracy of three techniques to determine cell viability in 3D tissues or scaffolds10.1089/ten.tec.2008.0313 ↗
38. Amnion-derived pluripotent/multipotent stem cells10.1007/s12015-006-0020-0 ↗
39. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells10.1186/s12890-018-0626-4 ↗
40. The effect of anti-inflammatory and antifibrotic agents on fibroblasts obtained from arthrofibrotic tissue: an in vitro and in vivo study10.1302/2046-3758.73.BJR-2017-0219.R2 ↗
41. Enhanced migration of fibroblasts derived from lungs with fibrotic lesions10.1136/thx.50.9.984 ↗
42. MicroRNA-146a-5p attenuates liver fibrosis by suppressing profibrogenic effects of TGFbeta1 and lipopolysaccharide10.1016/j.cellsig.2017.07.016 ↗
43. Freeze-drying of mammalian cells using trehalose: preservation of DNA integrity10.1038/s41598-017-06542-z ↗
44. The extracellular matrix: not just pretty fibrils10.1126/science.1176009 ↗
45. Human testis extracellular matrix enhances human spermatogonial stem cell survival in vitro
46. Extracellular matrix molecules enhance the neurotrophic effect of Schwann cell-like differentiated adipose-derived stem cells and increase cell survival under stress conditions10.1089/ten.tea.2012.0124 ↗
47. Adhesion dynamics: mechanisms and measurements10.1016/j.biocel.2008.04.008 ↗
48. Comparative characterization of cultured human term amnion epithelial and mesenchymal stromal cells for application in cell therapy10.3727/096368908786576507 ↗
49. Phenotypic shift of human amniotic epithelial cells in culture is associated with reduced osteogenic differentiation in vitro10.1080/14653240802345804 ↗
50. Enhanced osteogenesis of human mesenchymal stem cells by periodic heat shock in self-assembling peptide hydrogel10.1089/ten.tea.2012.0070 ↗
51. Anhydrobiosis: the extreme limit of desiccation tolerance
52. Pathogenesis of fibrosis: type 1 collagen and the skin10.1007/s001090050216 ↗
53. Tensile forces drive a reversible fibroblast-to-myofibroblast transition during tissue growth in engineered clefts10.1126/sciadv.aao4881 ↗
54. Biology of fibroblasts and myofibroblasts10.1513/pats.200708-146DR ↗
55. Hepatocyte growth factor and lung fibrosis10.1513/pats.201202-018AW ↗
56. Antifibrotic effects of hepatocyte growth factor on endothelial-to-mesenchymal transition via transforming growth factor-beta1 (TGF-beta1)/Smad and Akt/mTOR/P70S6K signaling pathways10.12659/AOT.906700 ↗
57. Interleukin-1beta attenuates myofibroblast formation and extracellular matrix production in dermal and lung fibroblasts exposed to transforming growth factor-beta110.1371/journal.pone.0091559 ↗
58. TGF-beta: the master regulator of fibrosis10.1038/nrneph.2016.48 ↗
59. Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical10.1163/156856208784909345 ↗
60. Targeting TGF-beta mediated SMAD signaling for the prevention of fibrosis10.3389/fphar.2017.00461 ↗
61. MicroRNAs and the regulation of fibrosis10.1111/j.1742-4658.2010.07632.x ↗
62. MicroRNAs in fibrosis: opportunities and challenges10.1186/s13075-016-0929-x ↗
63. MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1
64. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD10.1152/physiolgenomics.00039.2017 ↗
65. Role of microRNAs in fibrosis10.2174/1874312901206010130 ↗
66. microRNA expression profiles of scar and normal tissue from patients with posterior urethral stricture caused by pelvic fracture urethral distraction defects